Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Henna Butt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Virus Activation, Hepatitis B, Hepatitis B virus. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) can be cured by hematopoietic cell transplantation (HCT), but patients face increased risk of hepatitis B virus (HBV) reactivation due to immunosuppression. Understanding hepatitis B surface antibody (anti‐HBs) kinetics is essential for optimizing HBV revaccination and posttransplant care.
Methods
This post hoc analysis examined HBV immunity, reactivation, and revaccination response in 71 SCD patients who underwent HCT at the National Heart, Lung, and Blood Institute (2008–2021) using alemtuzumab and low‐dose total body irradiation.
Results
At baseline, 55% showed HBV immunity (anti‐HBs ≥ 12 mIU/mL). Most patients responded to revaccination regardless of baseline immunity. Post‐HCT revaccination was given to 93%, with 89% completing full series (Heplisav‐B or Engerix‐B). Vaccinated patients had a 67.5% chance of increased anti‐HBs titers between Years 1 and 2, though no significant difference was seen compared to unvaccinated patients ( p = 0.12). No HBV reactivation occurred; two patients with baseline HBcAb and HBsAg positivity showed decreasing HBV DNA levels.
Conclusions
Results indicate that HBV immunity can decline post‐HCT, but most patients remain immune, and revaccination is effective. However, some non‐responders—especially those treated with IVIG, rituximab, or prolonged immunosuppression—need further study. Prospective research is needed to optimize revaccination timing and immune monitoring in this high‐risk group. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
- Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Henna Butt, Matthew M Hsieh
Förderung
- Intramural NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Butt, H., Jeffries, N., Martin, T., De Giorgi, V., Zamora, A., Tisdale, J. F., & Hsieh, M. M. (2025). Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease. Transplant Infectious Disease. https://doi.org/10.1111/tid.70097
Vancouver
Butt H, Jeffries N, Martin T, De Giorgi V, Zamora A, Tisdale JF, et al. Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease. Transplant Infectious Disease. 2025. doi:10.1111/tid.70097
BibTeX
@article{Butt2025,
author = {Butt, Henna and Jeffries, Neal and Martin, Triscia and De Giorgi, Valeria and Zamora, Alison and Tisdale, John F and Hsieh, Matthew M},
title = {Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70097}
}
EUVIMED